BidaskClub downgraded shares of Neurocrine Biosciences (NASDAQ:NBIX) from a strong-buy rating to a buy rating in a report published on Tuesday.
Several other research firms have also weighed in on NBIX. Piper Jaffray Companies restated an overweight rating and set a $113.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, March 14th. Oppenheimer set a $110.00 price target on Neurocrine Biosciences and gave the company a buy rating in a research report on Tuesday, March 13th. Deutsche Bank lifted their price target on Neurocrine Biosciences to $97.00 and gave the company a buy rating in a research report on Wednesday, February 14th. Needham & Company LLC restated a buy rating and set a $110.00 price target (up from $95.00) on shares of Neurocrine Biosciences in a research report on Thursday, February 22nd. Finally, Leerink Swann lifted their price target on Neurocrine Biosciences from $90.00 to $96.00 and gave the company an outperform rating in a research report on Tuesday, February 20th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $95.23.
Shares of Neurocrine Biosciences (NBIX) opened at $81.49 on Tuesday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 10.20 and a current ratio of 10.20. Neurocrine Biosciences has a 1 year low of $39.21 and a 1 year high of $92.98. The firm has a market capitalization of $7,573.07, a P/E ratio of -49.69 and a beta of 0.31.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Tuesday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.11). The company had revenue of $94.52 million during the quarter, compared to the consensus estimate of $94.00 million. During the same quarter in the previous year, the company earned ($0.51) EPS. research analysts predict that Neurocrine Biosciences will post -0.23 EPS for the current fiscal year.
In other Neurocrine Biosciences news, insider Darin Lippoldt sold 15,237 shares of the business’s stock in a transaction on Thursday, December 28th. The stock was sold at an average price of $75.00, for a total value of $1,142,775.00. Following the sale, the insider now directly owns 28,394 shares of the company’s stock, valued at $2,129,550. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Haig P. Bozigian sold 75,873 shares of the business’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $90.00, for a total value of $6,828,570.00. Following the completion of the sale, the insider now directly owns 18,041 shares in the company, valued at $1,623,690. The disclosure for this sale can be found here. Insiders sold 399,589 shares of company stock worth $32,443,795 over the last three months. Corporate insiders own 4.80% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company raised its stake in shares of Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares during the last quarter. Nationwide Fund Advisors raised its stake in shares of Neurocrine Biosciences by 3.2% in the third quarter. Nationwide Fund Advisors now owns 124,351 shares of the company’s stock worth $7,620,000 after purchasing an additional 3,800 shares during the last quarter. Crossmark Global Holdings Inc. purchased a new position in shares of Neurocrine Biosciences in the third quarter worth $286,000. American Century Companies Inc. raised its stake in shares of Neurocrine Biosciences by 7.2% in the third quarter. American Century Companies Inc. now owns 36,148 shares of the company’s stock worth $2,215,000 after purchasing an additional 2,443 shares during the last quarter. Finally, Swiss National Bank raised its stake in shares of Neurocrine Biosciences by 1.3% in the third quarter. Swiss National Bank now owns 147,300 shares of the company’s stock worth $9,027,000 after purchasing an additional 1,900 shares during the last quarter.
TRADEMARK VIOLATION WARNING: This story was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2018/03/24/neurocrine-biosciences-nbix-downgraded-to-buy-at-bidaskclub.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.